No price history available.
Key financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | 1,338 | 1,318 | 1,525 | 1,853 | 2,034 | 2,248 | 2,582 | N/A | N/A |
| Operating profit | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | £m | 184 | 203 | 244 | 235 | 269 | 296 | 372 | N/A | N/A |
| EPS reported | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Value | ||||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | ||||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | ||||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | ||||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Halma plc, a company established in 1894 and headquartered in Amersham, United Kingdom, specializes in delivering innovative technological solutions across critical safety, health, and environmental sectors. Its operations are organized into three distinct divisions: Safety, Environmental & Analysis, and Medical. The Safety division offers a range of protective technologies, encompassing fire detection and advanced suppression systems, safety mechanisms for elevators, security sensors, and systems for managing pedestrian and vehicle movement. It also develops specialized interlocks for secure process control, as well as solutions for explosion prevention and corrosion oversight. These offerings cater to various applications, including elevator safety, fire management, crowd and traffic flow, industrial access, and secure storage solutions. Focused on monitoring and analysis, the Environmental & Analysis segment provides advanced optical, optoelectronic, and spectral imaging solutions. It also develops instruments for tracking water, air, and gas quality, including devices to detect hazardous gases and assess overall air purity, alongside comprehensive water analysis and treatment systems. Its expertise serves fields such as optical diagnostics, water management, gas detection, and broad environmental monitoring. The Medical division is dedicated to healthcare innovations, supplying essential fluidic components for medical diagnostics and original equipment manufacturers. It also produces laboratory instruments and platforms designed to provide crucial insights into patient health, aiding providers in clinical decision-making. Furthermore, the segment develops specialized technologies and approaches to facilitate in-vitro diagnostics, scientific discoveries, and product development in life sciences, ensuring beneficial outcomes across diverse medical specialties.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Halma plc, a company established in 1894 and headquartered in Amersham, United Kingdom, specializes in delivering innovative technological solutions across critical safety, health, and environmental sectors. Its operations are organized into three distinct divisions: Safety, Environmental & Analysis, and Medical. The Safety division offers a range of protective technologies, encompassing fire detection and advanced suppression systems, safety mechanisms for elevators, security sensors, and systems for managing pedestrian and vehicle movement. It also develops specialized interlocks for secure process control, as well as solutions for explosion prevention and corrosion oversight. These offerings cater to various applications, including elevator safety, fire management, crowd and traffic flow, industrial access, and secure storage solutions. Focused on monitoring and analysis, the Environmental & Analysis segment provides advanced optical, optoelectronic, and spectral imaging solutions. It also develops instruments for tracking water, air, and gas quality, including devices to detect hazardous gases and assess overall air purity, alongside comprehensive water analysis and treatment systems. Its expertise serves fields such as optical diagnostics, water management, gas detection, and broad environmental monitoring. The Medical division is dedicated to healthcare innovations, supplying essential fluidic components for medical diagnostics and original equipment manufacturers. It also produces laboratory instruments and platforms designed to provide crucial insights into patient health, aiding providers in clinical decision-making. Furthermore, the segment develops specialized technologies and approaches to facilitate in-vitro diagnostics, scientific discoveries, and product development in life sciences, ensuring beneficial outcomes across diverse medical specialties.